No article text was recorded for this version.
causal inference limitations in pharmacovigilance
Version 2 of 238 papers39 conceptsfrozen 2026-10-04
Papers in this version
- Blog: A supervised adverse drug reaction signalling framework imitating Bradford Hill's causality considerations
- Blog: Comparative safety signals of dopamine agonists: psychiatric and cardiovascular risks derived from FDA adverse event reporting system (FAERS) data
- Blog: A Pipeline to Understand Emerging Illness Via Social Media Data Analysis: Case Study on Breast Implant Illness
- Blog: Safety of antidepressants commonly used in 6–17-year-old children and adolescents: A disproportionality analysis from 2014–2023 on the basis of the FAERS database
- Blog: Cardiac adverse events associated with dual immune checkpoint inhibitors: a pharmacovigilance analysis from the FDA adverse event reporting system
- Blog: Liver injury in children: signal analysis of suspected drugs based on the food and drug administration adverse event reporting system
- Blog: Pharmacovigilance study on old drugs repurposed for rare diseases across different indications: the case of fenfluramine
- Blog: Clinical Judgement Study using Question Answering from Electronic Health Records
- Blog: Generalized enrichment analysis improves the detection of adverse drug events from the biomedical literature
- Blog: Using disproportionality analysis to explore the association between periostitis and triazole antifungals in the FDA Adverse Event Reporting System Database
- Blog: Adverse drug events associated with tiotropium: a real-world pharmacovigilance study of FDA adverse event reporting system database
- Blog: Feature Selection in Detection of Adverse Drug Reactions from the Health Improvement Network (THIN) Database
- Blog: Prevalence and Risk Factors for Opioid-Induced Constipation in an Older National Veteran Cohort
- Blog: Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
- Blog: Case Report: Associated Ocular Adverse Reactions With Inactivated COVID-19 Vaccine in China
- Blog: Machine learning risk prediction model for acute coronary syndrome and death from use of non-steroidal anti-inflammatory drugs in administrative data
- Blog: Drug-associated serotonin syndrome in elderly patients: a comprehensive disproportionality analysis based on the FAERS database
- Blog: Adverse Events of COVID-19 Vaccines in the United States: Temporal and Spatial Analysis
- Blog: Post-marketing risk analysis of bendamustine: a real-world approach based on the FAERS database
- Blog: Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system
- Blog: Comprehensive safety assessment of donepezil: pharmacovigilance analysis based on the FDA adverse event reporting system
- Blog: The real-world safety profile of empagliflozin: a disproportionality analysis based on the FDA Adverse Event Reporting System (FAERS) database
- Blog: Population-scale identification of differential adverse events before and during a pandemic
- Blog: Real-world database evaluation of drug-associated vitreous opacities and machine learning for clinical interpretability
- Blog: Automated gathering of real-world data from online patient forums can complement pharmacovigilance for rare cancers
- Blog: A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database
- Blog: Signal mining and analysis of trifluridine/tipiracil adverse events based on real-world data from the FAERS database
- Blog: Safety assessment of sapropterin dihydrochloride: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
- Blog: Drug-associated infections and infestations in older adults with tumor necrosis factor-alpha inhibitors: a real-world retrospective and pharmacovigilance study
- Blog: Investigating safety profiles of human papillomavirus vaccine across group differences using VAERS data and MedDRA
- Blog: Trivalent Influenza Vaccine Adverse Event Analysis Based On MedDRA System Organ Classes Using VAERS Data
- Blog: Death vs. Data Science: Predicting End of Life
- Blog: Adverse reactions of immune checkpoint inhibitors combined with Proton pump inhibitors: a pharmacovigilance analysis of drug-drug interactions
- Blog: Incorporating Spontaneous Reporting System Data to Aid Causal Inference in Longitudinal Healthcare Data
- Blog: Cardiovascular adverse events associated with targeted therapies for multiple myeloma: a pharmacovigilance study
- Blog: Predicting the Population Risk of Suicide Using Routinely Collected Health Administrative Data in Quebec, Canada: Model-Based Synthetic Estimation Study
- Blog: Frequent discussion of insomnia and weight gain with glucocorticoid therapy: an analysis of Twitter posts
- Blog: Detect adverse drug reactions for the drug Pravastatin
History & citation
Current · Permanent link
Cite this direction
Latest version (a living page):
@misc{lacuna_causal_inference_limitations_in_pharmaco_c6f2390b,
title = {causal inference limitations in pharmacovigilance},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/causal-inference-limitations-in-pharmacovigilance/rdr_c6f2390ba1c6411093e631ad51f27f77},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-19},
}This exact version (version 2, frozen text):
@misc{lacuna_causal_inference_limitations_in_pharmaco_c6f2390b_v2,
title = {causal inference limitations in pharmacovigilance},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/causal-inference-limitations-in-pharmacovigilance/rdr_c6f2390ba1c6411093e631ad51f27f77/v/2},
note = {Version 2, frozen 2026-10-04. Accessed 2026-11-19},
}